Active	Status	Sponsor type	Region	Phase	Filter
4 Active 4 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kozuma, Ken
ASET-JAPAN, NCT05117866: Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study	Active, not recruiting	N/A	307	Europe, Japan	prasugrel Monotherapy, PCI with the SYNERGY® stent	Meditrix Corp, Fujita Health University, Boston Scientific Japan K.K., National University of Ireland, Galway, Ireland	Chronic Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome	07/24	12/25
Kono, Hajime
ARRIA, NCT06611696: Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis	Not yet recruiting	4	160	Japan	Avacopan, prednisolone and rituximab, Prednisolone and rituximab	Chiba University, Kissei Pharmaceutical Co., Ltd., International University of Health and Welfare	ANCA Associated Vasculitis (AAV)	03/27	09/28
Komagata, Yoshinori
ARRIA, NCT06611696: Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis	Not yet recruiting	4	160	Japan	Avacopan, prednisolone and rituximab, Prednisolone and rituximab	Chiba University, Kissei Pharmaceutical Co., Ltd., International University of Health and Welfare	ANCA Associated Vasculitis (AAV)	03/27	09/28
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)	Recruiting	3	160	Europe, Canada, Japan, US, RoW	Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab	GlaxoSmithKline	Eosinophilic Granulomatosis With Polyangiitis	10/25	11/25